FDA Approves LENALIDOMIDE — Padagis US LLC

Padagis US LLC announced the FDA approval of its oral lenalidomide ANDA, positioning the company to compete in the generic oncology market where an influx of supply is expected to lower drug costs. This approval marks a strategic entry for the company into the multiple myeloma treatment sector, potentially intensifying competitive pricing.